SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Yu-Hsin Lin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

AUSTRALIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,253,935.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,253,935.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,253,935.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Notes to row 9: Yu-Hsin Lin is deemed to hold a total of 2,728,462 Ordinary Shares in Belite Bio, Inc, among which (i) 353,083 Ordinary Shares are directly held by Yu-Hsin Lin; (ii) 900,852 Ordinary Shares underlying share options and restricted stock units granted to Yu-Hsin Lin that are vested or will be vested within 60 days of March 31, 2026 are deemed to be held by Yu-Hsin Lin; and (iii) 1,474,527 Ordinary Shares are indirectly held by Yu-Hsin Lin through his shareholding in Lin BioScience, Inc., a public company listed on the OTC market in Taiwan (stock code: 6696.TW) and the parent company of Lin Bioscience International Ltd. Yu-Hsin Lin disclaims investment and disposition power of the 1,474,527 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin BioScience, Inc. and Lin Bioscience International Ltd. Notes to row 11: The percentage is calculated by dividing the number of Ordinary Shares beneficially owned by Yu-Hsin Lin by the aggregate of (i) 40,085,091 Ordinary Shares issued and outstanding as of March 31, 2026 as provided by the Issuer; and (ii) 900,852 Ordinary Shares underlying share options and restricted stock units granted to Yu-Hsin Lin that are vested or will be vested within 60 days of March 31, 2026 and are deemed to be beneficially owned by Yu-Hsin Lin.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

BELITE BIO, INC

(b)

Address of issuer's principal executive offices:

12750 High Bluff Drive Suite 475, San Diego, CA 92130, United States of America

Item 2.

(a)

Name of person filing:

This Schedule 13G is filed on behalf of Yu-Hsin Lin ("Reporting Person")

(b)

Address or principal business office or, if none, residence:

The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan

(c)

Citizenship:

Yu-Hsin Lin is a citizen of Australia

(d)

Title of class of securities:

Ordinary shares, par value US$0.0001 per share

(e)

CUSIP No.:

Item 4.

Ownership

(a)

Amount beneficially owned:

1,253,935

(b)

Percent of class:

3.1 % %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

1,253,935

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

1,253,935

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Yu-Hsin Lin

Signature:	/s/ Yu-Hsin Lin
Name/Title:	Yu-Hsin Lin, Chief Executive Officer and Chairman
Date:	05/14/2026